Half-life

—

Tmax

—

Category

peptide

Also known as: body protection compound 157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been studied predominantly in animal models for its purported angiogenic and tissue-healing properties. The proposed mechanism involves modulation of the nitric oxide (NO) pathway, vascular endothelial growth factor (VEGF) signalling, and tendon fibroblast activity. Its short half-life of approximately 4 hours reflects rapid enzymatic degradation in plasma. While human clinical data remain limited, BPC-157 is among the most commonly discussed peptides in biohacking communities. Anyone choosing to experiment with BPC-157 should maintain a detailed log of dosage, injection site, and any observed effects or side effects to facilitate informed discussions with their healthcare provider.

Mechanism

A synthetic peptide sequence derived from a gastric protective protein. In animal models it has been associated with angiogenic and growth-factor modulating activity; the mechanism in humans is not well characterized.

Research summary

Most published evidence is preclinical (rodent) work on tissue repair and gastrointestinal protection. It is not FDA-approved, and rigorous human clinical trial data are limited. Claims should be read against that evidence gap. In July 2026 an FDA advisory committee (the Pharmacy Compounding Advisory Committee) voted to recommend this compound for the 503A bulk-compounding list. That recommendation is non-binding and is not FDA approval — it would still require formal rulemaking, and no approved clinical evidence of safety or efficacy exists.

Reported side effects

Because controlled human safety data are limited, the side-effect and long-term safety profile is largely unknown. Product purity and source are common quality concerns raised in the literature.

Educational summary of published research. Not dosing guidance or medical advice.

Sources

BPC-157 pharmacokinetics · literature reviewNo published human pharmacokinetics. Animal work suggests minutes-scale clearance; no human half-life is shown.

References

BPC-157 reviewDOI: 10.3390/biomedicines10010162

Το TrackPep είναι εφαρμογή παρακολούθησης. Καταγράφει όσα καταχωρίζεις και ποτέ δεν προτείνει ούτε υπολογίζει ποσότητες.